/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $142.8 billion by market cap, the company’s primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions.
Shares of this HIV giant have outperformed the broader market over the past year. GILD has gained 47% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 17%. In 2025, GILD stock is up 24.2%, surpassing the SPX’s 8.2% rise on a YTD basis.
Zooming in further, GILD’s outperformance is also apparent compared to the Invesco Pharmaceuticals ETF (PJP). The exchange-traded fund has declined about 4.4% over the past year. Moreover, GILD’s double-digit gains on a YTD basis outshine the ETF’s marginal dip over the same time frame.
On Apr. 24, GILD shares closed down marginally after reporting its Q1 results. Its adjusted EPS of $1.81 missed Wall Street's expectations of $1.82. The company’s revenue was $6.7 billion, falling short of Wall Street forecasts of $6.8 billion. GILD expects full-year adjusted EPS in the range of $7.70 to $8.10.
For the current fiscal year, ending in December, analysts expect GILD’s EPS to grow 73.6% to $8.02 on a diluted basis. The company’s earnings surprise history is mixed. It beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.
Among the 28 analysts covering GILD stock, the consensus is a “Moderate Buy.” That’s based on 18 “Strong Buy” ratings, two “Moderate Buys,” and eight “Holds.”
This configuration is more bullish than a month ago, with one analyst suggesting a “Moderate Buy.”
On Jul. 28, BMO Capital analyst Evan Seigerman maintained a “Buy” rating on GILD with a price target of $120, implying a potential upside of 4.6% from current levels.
The mean price target of $119.15 represents a 3.8% premium to GILD’s current price levels. The Street-high price target of $140 suggests an upside potential of 22%.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
